

4 Lei Shi<sup>1,2\*</sup>, Hai Huang<sup>3,4\*</sup>, Xuechun Lu<sup>2,5\*</sup>, Xiaoyan Yan<sup>6\*</sup>, Xiaojing Jiang<sup>7</sup>, Ruonan Xu<sup>1</sup>,  
 5 Siyu Wang<sup>1</sup>, Chao Zhang<sup>1,2</sup>, Xin Yuan<sup>1,2</sup>, Zhe Xu<sup>1,2</sup>, Lei Huang<sup>1,2</sup>, Jun-Liang Fu<sup>1,2</sup>,  
 6 Yuanyuan Li<sup>1</sup>, Yu Zhang<sup>8,9</sup>, Weiqi Yao<sup>9,10</sup>, Tianyi Liu<sup>2,11</sup>, Jinwen Song<sup>1,2</sup>, Liangliang  
 7 Sun<sup>4,12</sup>, Fan Yang<sup>13</sup>, Xin Zhang<sup>2,14</sup>, Bo Zhang<sup>7</sup>, Ming Shi<sup>1</sup>, Fanping Meng<sup>1</sup>, Yanning Song<sup>1</sup>,  
 8 Yongpei Yu<sup>6</sup>, Jiqiu Wen<sup>2</sup>, Qi Li<sup>2</sup>, Qing Mao<sup>2</sup>, Markus Maeurer<sup>16,17</sup>, Alimuddin Zumla<sup>18</sup>,  
 9 Chen Yao<sup>6#</sup>, Wei-Fen Xie<sup>4,15#</sup>, Fu-Sheng Wang<sup>1,2#</sup>

10

- 11 1. Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General  
12 Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.  
13 2. Wuhan Huoshenshan Hospital, Wuhan, China.  
14 3. Department of Respiratory, Changzheng Hospital, Second Military Medical University,  
15 Shanghai, China.  
16 4. Optical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan,  
17 China.  
18 5. Department of Hematology, Second Medical Center of Chinese PLA General Hospital,  
19 Beijing, China.  
20 6. Peking University Clinical Research Institute, Peking University First Hospital, Beijing,  
21 China.  
22 7. Department of Infectious Disease, General Hospital of Central Theater Command,  
23 Wuhan, China.

24 8. VCANBIO Cell & Gene Engineering Corp., Ltd. Tianjin, China.  
25 9. National Industrial Base for Stem Cell Engineering Products, Tianjin, China.  
26 10. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong  
27 University of Science and Technology, Wuhan, China.  
28 11. Key Laboratory of Cancer Center, Fifth Medical Center of Chinese PLA General  
29 Hospital, Beijing, China.  
30 12. Department of Endocrinology and Metabolism, Changzheng Hospital, Second Military  
31 Medical University, Shanghai, China.  
32 13. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong  
33 University of Science and Technology, Wuhan, China.  
34 14. Nursing Department, Fifth Medical Center of Chinese PLA General Hospital, Beijing,  
35 China.  
36 15. Department of Gastroenterology, Changzheng Hospital, Second Military Medical  
37 University, Shanghai, China.  
38 16. Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal.  
39 17. I Med Clinic, University of Mainz, Mainz, Germany.  
40 18. Center for Clinical Microbiology, Division of Infection and Immunity, University  
41 College London, and UCL Hospitals NIHR Biomedical Research Centre, London, UK  
  
42 \* Drs. Lei Shi, Hai Huang, Xuechun Lu and Xiaoyan Yan contributed equally to this  
43 article.

44 ***Correspondence to:***

45 # Prof. Fu-Sheng Wang, Department of Infectious Diseases, Fifth Medical Center of  
46 Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases,

47 No.100 Western 4th Ring Road, Beijing 100039, China. [fswang302@163.com](mailto:fswang302@163.com)  
48 # Prof. Wei-Fen Xie, Department of Gastroenterology, Changzheng Hospital, Second  
49 Military Medical University, 415 Fengyang Road, Shanghai, 200003, China.  
50 [weifenxie@medmail.com.cn](mailto:weifenxie@medmail.com.cn)  
51 # Prof. Chen Yao, Peking University Clinical Research Institute, Peking University First  
52 Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China  
53 [yaochen@hsc.pku.edu.cn](mailto:yaochen@hsc.pku.edu.cn)

54    **Abstract**

55    **Objective**

56    To assess the safety and efficacy of human umbilical cord-derived MSCs (UC-MSCs) for  
57    severe COVID-19 patients with lung damage.

58    **Design,**

59    Multicentre, randomised, double-blind, placebo-controlled trial.

60    **Setting**

61    Two hospitals in Wuhan, China, 5 March 2020 to 28 March 2020.

62    **Participants**

63    101 severe COVID-19 patients with lung damage aged between 18–74 years.

64    **Intervention**

65    Patients were randomly assigned at a 2:1 ratio to receive either UC-MSCs ( $4 \times 10^7$  cells  
66    per infusion) or placebo on days 0, 3, and 6.

67    **Main outcome measures**

68    The primary endpoints were safety and an altered proportion of whole lung lesion size  
69    from baseline to day 28, measured by chest computed tomography. Secondary outcomes  
70    were reduction of consolidation lesion size and lung function improvement (6-minute walk  
71    test, maximum vital capacity, diffusing capacity). Primary analysis was done in the  
72    modified intention-to-treat (mITT) population and safety analysis was done in all patients  
73    who started their assigned treatment.

74    **Results**

75    100 patients were finally recruited to receive either UC-MSCs ( $n = 65$ ) or placebo ( $n = 35$ ).  
76    The patients receiving UC-MSCs exhibited a trend of numerical improvement in whole  
77    lung lesion size from baseline to day 28 compared with the placebo cases (the median  
78    difference was -13.31%, 95%CI -29.14%, 2.13%,  $P=0.080$ ). UC-MSCs administration

79 significantly reduced the proportions of consolidation lesion size from baseline to day 28  
80 compared with the placebo (median difference: -15.45%, 95% CI -30.82%, -0.39%,  
81 P=0.043). The 6-minute walk test showed an increased distance in patients treated with  
82 UC-MSCs (difference: 27.00 m, 95% CI 0.00, 57.00, P=0.057). The incidence of adverse  
83 events was similar, and no serious adverse events were observed in the two groups.

84 **Conclusions**

85 UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19  
86 patients with lung damage. A phase 3 trial is required to evaluate effects on reducing  
87 mortality and preventing long-term pulmonary disability.

88 **Trial registration**

89 ClinicalTrials.gov Identifier: NCT04288102

90    **Key Points**

91    **Question**

92    Are human umbilical cord-derived mesenchymal stem cells (UC-MSCs) safe and effective  
93    therapeutic option for limiting lung damage in severe coronavirus disease 2019  
94    (COVID-19)?

95    **Finding**

96    In this randomised, double-blind, placebo-controlled, phase 2 trial that included 100  
97    COVID-19 patients with lung damage, human UC-MSCs medication showed a trend of  
98    improvement in whole lung lesion size and significantly reduced the proportions of  
99    consolidation lesions from baseline to day 28 in the treated patients compared with the  
100   placebo subjects. The 6-minute walk test showed a longer distance in UC-MSCs than  
101   placebo group but without significantly difference. UC-MSCs delivery was well tolerated,  
102   with no serious adverse events.

103   **Meaning**

104   Human UC-MSC administration for hospitalized COVID-19 with lung damage is safe.  
105   Treatment with human UC-MSC improves the resolution of lung lesions, particularly the  
106   consolidation lesions.

107  
108

109 **Introduction**

110 The Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome  
111 coronavirus 2 (SARS-CoV-2) infection,<sup>1</sup> causes substantial damage to lungs, ranging from  
112 mild respiratory illness to severe acute respiratory syndrome, and death.<sup>2-4</sup> Dysregulated  
113 immune responses of both the innate and adaptive immune systems are associated with  
114 disease severity, lung damage and long term functional disability.<sup>5-8</sup> There are currently no  
115 prophylactic vaccines or effective antiviral agents available to treat COVID-19 and  
116 management of COVID-19 patients remains largely symptomatic and supportive therapy.<sup>9</sup>  
117 Therefore, there is an urgent need for safe and alternative therapeutic options to mitigate  
118 inflammatory organ injury. Currently ongoing clinical trials of immunotherapeutic  
119 approaches include convalescent plasma therapy, monoclonal antibodies against  
120 interleukin-6, and cellular therapies.<sup>10-12</sup> Mesenchymal stem cells (MSC) are  
121 non-hematopoietic cells with immune modulatory, regenerative, and differentiation  
122 properties.<sup>13</sup> MSC treatment reduced the pathological changes of the lung and inhibits the  
123 cell-mediated immune-inflammatory response induced by the influenza virus in animal  
124 models and clinical trials.<sup>14 15</sup> The safety and potential efficacy of MSC have also been  
125 evaluated in the patients with acute respiratory distress syndrome (ARDS).<sup>16-19</sup> The  
126 immunomodulatory and regenerative properties of MSCs offer potential cellular  
127 therapeutic option for limiting lung damage in patients with COVID-19 and require  
128 evaluation in randomised controlled. In a phase 1 trial we previously demonstrated that  
129 intravenous transfusions of human umbilical cord (UC)-MSCs in patients with moderate  
130 and severe COVID-19 were safe and well tolerated (NCT04252118).<sup>20</sup> We now report  
131 results of a randomised, double-blind, placebo-controlled trial performed at 2 medical  
132 centers in Wuhan, China, evaluating the safety and efficacy of intravenous treatment with  
133 UC-MSCs in severe COVID-19 patients with lung damage.

134 **Methods**

135 **Trial sites:**

136 This investigator-initiated, randomised, placebo-controlled, double-blind phase II trial was  
137 carried out at two COVID-19 designated hospitals in Wuhan city, Hubei Province, China.  
138 Patients' follow-up procedures were conducted at a third hospital after discharge. The  
139 clinical protocol and statistical analysis plan are available in Supplement 1 and Supplement  
140 2.

141 **Inclusion and Exclusion Criteria**

142 Hospitalised patients with severe COVID-19 with laboratory-confirmed SARS-CoV-2  
143 infection by reverse transcription polymerase chain reaction (RT-PCR) were screened.  
144 Patients were eligible if they met any of the following criteria: 1) severe COVID-19  
145 diagnosed after onset of disease; 2) chest computed tomography (CT) imaging confirmed  
146 pneumonia combined with lung damage. The illness severity of COVID-19 was evaluated  
147 in accordance with Guidelines issued by the National Health Commission of China  
148 (version 7.0).<sup>21</sup> Briefly, patients with any of the following conditions but without invasive  
149 ventilation, shock or other organ failure (need organ support therapy) were considered as  
150 severe cases: 1) dyspnoea (respiratory rate  $\geq$  30 times/min); 2) oxygen saturation of 93%  
151 or lower on room air; 3) arterial oxygen partial pressure ( $\text{PaO}_2$ )/fraction of inspired oxygen  
152 ( $\text{FiO}_2$ )  $\leq$  300 mmHg; 4) pulmonary imaging showing that the foci progressed by > 50% in  
153 24-48 hours. The exclusion criteria included patients with shock or COVID-19 combined  
154 with any one of other organ failures, those who received invasive ventilation, or patients  
155 with any malignant tumour, pregnancy or breastfeeding, or co-infection of other pathogens.

156 **Randomization and masking**

157 Eligible patients were randomly assigned in a 2:1 ratio to receive either UC-MSCs or the

158 placebo, in addition to standard care, using an interactive web response management  
159 system (IWRS). A permuted-block randomisation sequence that was stratified by the trial  
160 sites was generated and uploaded to the system. Patients, investigators, and outcome  
161 assessors (independent central imaging reviewers) were all blinded to the treatment  
162 allocation. Blinding was also ensured by the product marking, with the UC-MSCs and the  
163 placebo having a similar appearance and packaging.

164 A barcode-based product management system (Product Identification Authentication  
165 and Tracking System, PIATS) was introduced in this study to manage and track the study  
166 products logistics, e.g., preparation, packaging, shipping, storage, and clinical  
167 administration to the patients. The application of PIATS could realize the blind label  
168 processing by non-informative unique barcodes of the clinical study drug. The  
169 concealment of the randomisation sequence could be ensured using PIATS and IWRS.

#### 170 **UC-MSCs preparation, dosage, and safety monitoring**

171 UC-MSCs were prepared by VCANBIO Cell & Gene Engineering Corp, Tianjin, China.  
172 Briefly, the MSCs were obtained according to the method described in our previous  
173 study.<sup>20</sup> The UC-MSCs used in this study came from one umbilical cord of full-term  
174 deliveries (after consultation with the parents of UC donor). The Wharton's Jelly (WJ)  
175 tissues were cut into approximately 2 mm<sup>3</sup> pieces from cord tissue and planted upside  
176 down on tissue culture flasks (75 cm<sup>2</sup>) cultured in DMEM/F12, supplemented with fetal  
177 bovine serum (10% FBS, BI, Israel) at 37°C with 5% CO<sub>2</sub>. The adherent cells were  
178 detached with 1×TrypLE (GIBCO, USA) and then re-plated at a density of approximately  
179 6-8×10<sup>3</sup> cells/cm<sup>2</sup> for further expansion. Master cell bank at passage 2 and working cell  
180 bank at passage 4 were set separately. A homogenous population of cultured cells at  
181 passage 5 were prepared as UC-MSC product. The culture cells were identified by the  
182 minimal criteria suggested by International Society for Cellular Therapy(ISCT): (1) plastic

183 adherent under tissue culture flask; (2) >95% of the cell population expressed CD105,  
184 CD73 and CD90, and these cells were lack expression (<2% positive) of CD45, CD34,  
185 CD11b, CD19 and HLA-DR as measured by flow cytometry (BD, FACS Calibur, USA); (3)  
186 differentiation potential into osteoblasts, adipocytes and chondroblasts under standard in  
187 vitro differentiating conditions. For each individual MSC batch, cell viability was  
188 examined using both trypan blue and 7-AAD/Annexin V staining by flow cytometry after  
189 preparation in Tianjin and before intravenous transfusion in Wuhan, respectively  
190 (Supplement 3). The cell product has been certified by the National Institutes for Food and  
191 Drug Control of China.

192 The UC-MSC product was an almost colourless suspension containing  $4.0 \times 10^7$   
193 MSCs in a volume of 100 ml/bag. The placebo had the same medium and appearance in  
194 packaging and suspension, but without the MSCs. After preparation, both the MSC and  
195 placebo products were shipped to the clinical facilities in an ice box with a real-time  
196 monitoring and alarm device for temperature and location to ensure the best storage  
197 conditions (8–12 °C). Shipping of cell products by express railway from Tianjin to Wuhan  
198 took less than 6 hours.

199 The treatment dose was  $4.0 \times 10^7$  cells for each procedure, and three procedures were  
200 carried out for each patient on day 0, 3, and 6 after randomisation. Infusion was started  
201 with a standard blood filter tubing set with a pore size of 170 µm. Under  
202 electrocardiographic monitoring, the cell product was infused by gravity within 60 min.  
203 We also monitored continuous pulse oximetry as well as patient's physical signs including  
204 body temperature, pulse, skin color, respiration, and blood pressure during the infusion  
205 period and up to 30 min after infusion.

206 The incidence and nature of all adverse events were reviewed and assessed by the  
207 investigators to determine whether they were related to the administration of the study

208 product. Methods for data collection and in-study measurements are described in detail in  
209 Supplement 1.

210 **Imaging and clinical outcomes**

211 All patients underwent high-resolution chest CT examination at baseline, day 10, and day  
212 28. The primary outcome was gauged as a change in the total lesion proportion (%) of the  
213 whole lung volume from baseline to day 28, as measured by chest CT. It was defined as  
214 (total lesion proportion of the whole lung volume at day 28–total lesion proportion of the  
215 whole lung volume at baseline) / total lesion proportion of the whole lung volume at  
216 baseline. The secondary imaging outcomes were a change in the total lesion proportion (%)  
217 of the whole lung volume from baseline to day 10, a change in consolidation and  
218 ground-glass lesion proportion from baseline to day 10, 28 , and change in lung  
219 densitometry at day 10, 28. Lung lesions were evaluated by using the changes in  
220 high-resolution chest CT images and measured by centralised imaging interpretation based  
221 on both lung radiologist analyses and imaging software. The imaging data were derived  
222 from a software-assisted lung volumetry and densitometry procedure (Supplement 1).

223 Clinical outcomes within 28 days included 6-minute walk test (6-MWT), status of  
224 oxygen therapy maximum forced vital capacity ( $VC_{max}$ ), diffusion lung capacity for carbon  
225 monoxide ( $DL_{CO}$ ), modified Medical Research Council Dyspnoea Scale (mMRC), changes  
226 in absolute lymphocyte counts and subsets, as well as plasma cytokine and chemokine  
227 levels. Safety evaluation included adverse events and all-cause mortality. Detailed  
228 definitions and assessment procedures are described in Supplement 1.

229 **Statistical analysis**

230 This study was designed as a phase 2 clinical trial. The limited efficacy information of the  
231 medication in patients with COVID-19 and the exploratory nature of this study meant that

232 the original target sample size was not justified by statistical calculation and was set as 45  
233 patients, with an allocation ratio of 2:1. Minimal serious adverse events were observed in  
234 our phase 1 trial; therefore, the sample size was expanded to 90, and finalized at 101, to  
235 obtain more data from this study. Sample size adjustments were made in a manner that  
236 maintained the double-blind status of this study and were approved by the institutional  
237 review boards of the two participating hospitals.

238 There were no pre-defined hypotheses made in this study; therefore, we focused on  
239 description instead of inference for statistical analyses: all statistical tests, confidence  
240 intervals, and *P*-values were used for exploration, not for inference. For primary outcome  
241 analysis – the change in the total lesion proportion (%) of the whole lung volume from  
242 baseline to day 28 and the difference between the UC-MSC and placebo groups was tested  
243 using wilcoxon rank sum test and the median differences were calculated using the  
244 Hodges–Lehmann estimation (It was also applied to other secondary outcomes which were  
245 not in accordance with normal distribution.). Six category scale and MMRC dyspnea score  
246 were calculated by using ordinal logistic regression model. The modified intention-to-treat  
247 (mITT) population was considered as the primary analysis population and safety analysis  
248 was done in all patients who started their assigned treatment. If the patient missed a chest  
249 CT scan, the last scan's results were carried forward to the missing visit for primary  
250 endpoints in the mITT analysis. Other missing values of secondary endpoints and  
251 per-protocol analyses were not imputed. Statistical analyses were performed using SAS  
252 software, version 9.4 (Cary, NC, USA). The figures were generated using GraphPad Prism  
253 7 software (GraphPad Inc., La Jolla, CA, USA).

254 **Patient and public involvement**

255 No patients were involved in setting the outcome measures, nor were they involved in  
256 developing plans for recruitment, design, or implementation of the study. No patients were

257 asked to advice on interpretation or writing up the results. All participants will be informed  
258 of the trial results by telephone or email. The trial results will be disseminated to the public

259 through public media.

260

261 **Results**

262 **Study Population**

263 From March 5, 2020, to March 28, 2020, a total of 288 patients were screened at two  
264 hospitals in Wuhan city. The majority of severe hospitalized COVID-19 patients were at  
265 the convalescent stage and some of them were with progression stage. Among them, 101  
266 eligible patients previously diagnosed as severe COVID-19 type, being referred as the ITT  
267 population, were randomised in a 2:1 ratio (66 to the UC-MSC group and 35 to the placebo  
268 group). One patient in the treatment group withdrew her previously written informed  
269 consent after randomisation and did not receive UC-MSC infusion. Therefore, 65 and 35  
270 patients were treated with UC-MSC or placebo, respectively, who were defined as the  
271 modified intention-to treat (mITT) population, as shown in Figure 1. Some patients missed  
272 the follow-up check on day 28 or received the examination outside of the follow-up  
273 window; therefore, the per-protocol (PP) population included 49 patients in the MSC group  
274 and 25 patients in the placebo group (Supplement 4).

275 **Baseline characteristics**

276 The baseline characteristics were highly consistent between the two groups of patients  
277 in the mITT population (Table 1). Briefly, baseline age, sex, BMI, time from symptom  
278 onset, distribution of comorbidities, concomitant medication, and lesion proportions  
279 assessment from chest CT were matched in the two groups. The median time from  
280 symptoms onset to study baseline was 45.00 (39.00, 51.00) days in the MSC group and  
281 47.00 (41.00, 53.00) days in the placebo group. The most common comorbidity was  
282 hypertension, followed by diabetes. The majority of the patients at baseline has a clinical  
283 status of category 2 or category 3, as shown by evaluation of the Six Category Scale. In  
284 detail, there were 14 (21.54%), 50 (76.92%), and 1 (1.54%) patients in category 2, 3, and 4,  
285 respectively, at baseline in the MSC group; and 10 (28.57%), 25 (71.43%), 0 (0.00%) in

286 category 2, 3, and 4, respectively, in the placebo group. There were no statistical  
287 differences in laboratory results, including D-dimer, interleukin-6 (IL-6), and C-reactive  
288 protein (CRP) between the two groups.

289 **Imaging and clinical outcomes**

290 To evaluate the difference in the primary endpoint and parts of the secondary endpoints, we  
291 analysed the changes in high-resolution chest CT images and measured the lesions by  
292 using centralised imaging interpretation based on the evaluation of both radiologist  
293 analyses and lung imaging artificial intelligence software. Through comparison of the  
294 Hodges-Lehmann estimator of the total lesion proportion (%) of the whole lung volume,  
295 the median change was -19.40% (95% CI, -53.40%, -2.62%) in the MSC group, and -7.30%  
296 (95%CI, -46.59%, 19.12%) in the placebo group on day 28 from baseline, yielding a  
297 difference of -13.31% (95% CI, -29.14%, 2.13%,  $P= .080$ ) (Figure 2, Table 2, Supplement  
298 5). Interestingly, in the evaluation of the consolidation lesions as a specific lesion type, we  
299 found that the median change from baseline to day 28 were -57.70% (95%CI, -74.95%,  
300 -36.56%) and -44.45% (95% CI, -62.24%, -8.82%) in the MSC and placebo groups,  
301 respectively, leading to a significant difference between the MSC group and placebo group  
302 (95% CI -30.82%, -0.39%,  $P= .043$ ). We also observed decrease in the ground-glass  
303 lesions in the MSC group than the placebo group, although the difference was not  
304 statistically significant. To exclude the effect of missing data on the outcomes of the above  
305 results in some mITT cases, we further analysed the PP population. Almost identical results  
306 between the two groups were obtained, as shown in Supplement 6 and 7.

307 To compare the restoration of lung function and integrated reserve capability among  
308 the two groups of patients, we examined the 6-MWT on the 28th day after the onset of  
309 treatment and found that 6-minute walking distance was longer in the MSC group (median  
310 420.00 meters [interquartile range (IQR) 392.00,465.00]) than in the placebo group

311 (median 403.00 meters [IQR 352.00,447.00]) with a 95% CI of 0.00–57.00 ( $P=.057$ , Table  
312 2). Other parameters including VCmax and DLco, the six-category scale, status of oxygen  
313 therapy and mMRC dyspnoea score were similar between the two groups (Table 2). In  
314 addition, there was no significant difference in the subsets of peripheral lymphocyte counts  
315 (CD4+ T cells, CD8+ T cells, B cells, NK cells) and plasma markers between the two  
316 groups (Supplement 8).

317 **Post Hoc Analyses**

318 We have established five models in three analysis data sets (mITT, PPS and ITT) for  
319 sensitivity analyses of primary end point (Supplement 9). The five models included:  
320 treatment group factor was included in model 1, treatment group and center factors were  
321 included in model 2 as fixed effects, and treatment group, baseline and center factors were  
322 included as fixed effects in model 3, center factor was included as random effect, treatment  
323 group factor was included as fixed effects in model 4, center factor was included as  
324 random effect, treatment group and baseline factors were included as fixed effects in model  
325 5. The conclusions of all models were consistent with those of univariate analysis.

326 **Safety**

327 The incidence of adverse events reported during the study was similar in the MSC group  
328 (55.38%) and the placebo group (60%) (Table 3). The most common adverse event in the  
329 MSC group was an increase in lactic acid dehydrogenase (13.85%), compared with 20% in  
330 the placebo group; a 10.77% elevation of serum alanine aminotransferase compared with  
331 11.43% in the placebo group; a 9.23% increase in hypokalaemia compared with 2.86% in  
332 the placebo group; a 7.69% increase in aspartate aminotransferase compared with 11.43%  
333 in the placebo group; and a 7.69% increase in hyperuricemia compared with 8.75% in the  
334 placebo group. Only one case experienced a grade 3 adverse event (pneumothorax) in the

335 MSC group, which recovered spontaneously under conservative treatment. There were few  
336 other adverse events at grade 1 or 2 in both groups. All adverse events during the  
337 observation period were judged by the site investigators and found to be unrelated to  
338 UC-MSC intervention. No deaths were observed in this trial.

339 **Discussion**

340 Whilst several trials of the therapeutic use of MSCs for patients with COVID-19 have been  
341 registered at Clinicaltrial.gov, there are no data available to date from randomised  
342 placebo-controlled clinical trials yet. This is the first report of a double-blind, randomised,  
343 and controlled phase 2 trial, in COVID-19 patients with lung damage. Our data found that  
344 UC-MSC administration was safe and well tolerated and exerted a trend of improvement in  
345 whole lung lesion for COVID-19 patients. More interestingly, UC-MSC medication  
346 significantly increased the resolution of lung consolidation lesions compared with the  
347 placebo. The data from the 6-MWT data show an improved restoration of the integrated  
348 reserve capability in the UC-MSC-treated patients. These findings indicate that the use of  
349 UC-MSC as adjunctive therapy to standard of care treatment for patients with COVID-19  
350 is a viable option. Recently, MSCs have been approved conditionally by the US-FDA  
351 under what is known as ‘expanded access compassionate use’ for COVID-19 patients. A  
352 phase 3 trial is now required to further evaluate effects on mortality and long term  
353 pulmonary disability, and to determine the underlying mechanisms of UC-MSC treatment  
354 for COVID-19 disease.<sup>22</sup>

355 COVID-19 is characterized by pathological lung changes in both the parenchyma  
356 and interstitium<sup>2</sup>, including ground glass opacity, consolidation, traction bronchiectasis,  
357 reticulation, and thickening of the bronchovascular bundles, as imaged using chest CT<sup>23</sup>.  
358 Notably, the improvement of pulmonary lesions, especially the improvement of pulmonary

359 interstitial lesions, directly affects the recovery of lung function and the remission of  
360 clinical symptoms.<sup>24</sup> The outbreak of COVID-19 occurred in China in January and early  
361 February, and was basically brought under control in March. As enrolment ensured, many  
362 severe hospitalized COVID-19 patients were at the convalescent stage and some of these  
363 patients in the progression stage, which presented a challenge to explore clinical  
364 improvement. Considering lung damage was still a common characteristic in these patients  
365 at convalescent phase which affected their recovery and life quality, we modified the  
366 primary outcome to the change in the total lesion proportion (%) of the whole lung volume  
367 as measured by CT from baseline to day 28. The patients enrolled in this study were all  
368 previously diagnosed as severe types, with a longer disease course and older age,  
369 compared with the recent studies.<sup>25,26</sup> In particular, all the patients suffered from serious  
370 pulmonary damage and needed oxygen inhalation support during the course of disease. Our  
371 current trial showed that UC-MSCs therapy improved the resolution of the whole lung  
372 damage size, as detected by CT scanning, particularly the consolidation lesions. This finding  
373 indicated that UC-MSC administration has a therapeutic benefit for patients with  
374 COVID-19, even in the convalescent stage. It is known that the consolidation lesions in the  
375 lung include the interstitial fibrosis. Thus, the improvements of consolidation lesions might  
376 also imply the alleviation of lung fibrosis.

377 The 6-MWT has been used to evaluate patients suffering from a variety of  
378 cardiopulmonary diseases. The results reflect the integrated reserve capability of complex  
379 physiology, involving the pulmonary and cardiovascular systems, and neuromuscular  
380 circulation<sup>27</sup>. In this trial, the 6-MWT was numerically, but not statistically, improved in  
381 the MSC group compared with that in the placebo group. Given that there was no  
382 significant difference in cardiovascular diseases between the two groups and no

383 cerebrovascular diseases in both groups at baseline, the findings from the 6-MWT data  
384 imply that capacity for aerobic exercise was potentially improved in the UC-MSCs group.

385 It is hypothesized that the beneficial effect of MSC treatment for patients with severe  
386 COVID-19 is mediated via reduction of pro-inflammatory cytokines, that jointly mediate  
387 immune pathology and worsen clinical COVID-19 outcomes.<sup>7,28-30</sup> Cytokines such as  
388 serum IL-6 are considered as biologically relevant biomarkers associated with disease  
389 progression of COVID-19. In this study, UC-MSC infusion did not result in a significant  
390 reduction in the duration of oxygen therapy, mMRC, cytokine, or chemokine levels, which  
391 might be in part attributed to the status of the enrolled population, since most of them were  
392 not in the acute progressive stage. Other mechanisms of actions have to be explored for  
393 MSCs that are measurable in the systemic circulation. We could not, however, measure the  
394 local, i.e. intrapulmonary, effects of MSC delivery. It could very well be that the local  
395 MSC-mediated effects were not measurable in the systemic circulation, a similar scenario  
396 as in MSC treatment of patients with corticosteroid-resistant graft-versus-host-disease  
397 (GVHD).

398 In our trial, a total of three doses of  $4 \times 10^7$  UC-MSCs were transfused for each  
399 patient. No MSC-related predefined haemodynamic or respiratory adverse events were  
400 observed. The incidences of adverse events were similar between the MSC group and the  
401 placebo group. Only one patient in the MSC group suffered a pneumothorax that was  
402 judged to be unrelated to UC-MSC medication. No patient died during the follow-up period.  
403 The safety profile of the UC-MSCs confirms the results of our previous phase 1 trial<sup>20</sup> and  
404 other MSC studies.<sup>31,32</sup> These data suggested that UC-MSC therapy was well tolerated and  
405 very safe. In view of the ongoing clinical trials with higher dose of MSCs used in other  
406 groups in China, America, and Europe,<sup>22</sup> more safety data are expected in the near future.

407 **Limitations**

408 There were several operational limitations to our study. A larger sample size could  
409 have improved efficacy analyses. According to management guidelines issued by the  
410 Chinese National Health Commission (7<sup>th</sup> edition),<sup>21</sup> patients with COVID-19 require  
411 further centralized isolation for 14 days after discharge. In this setting, some of the patients  
412 missed the follow-up data at day 28, but they did receive a follow-up check around 7–10  
413 days after the 28-day follow-up window. Importantly, our PP population analysis also  
414 revealed similar results compared with mITT population analysis. Whether the cell dosage,  
415 interval duration, and cycles of UC-MSC medication were the best regimen for patients  
416 with severe COVID-19 were not fully investigated in this study.

417 **Conclusion and future implications**

418 To the best of our knowledge, this is the first randomised, double-blind,  
419 placebo-controlled trial evaluating the safety and preliminary efficacy of UC-MSCs as a  
420 potential treatment for patients with COVID-19 with lung damage, even at the  
421 convalescent stage. UC-MSC administration was safe and accelerated resolution of lung  
422 consolidation lesions and improvement in the integrated reserve capability after UC-MSC  
423 administration. UC-MSCs treatment offers a safe and potentially effective therapeutic  
424 approach for COVID-19 patients with lung damage. A phase 3 trial is required to further  
425 evaluate effects on preventing long-term pulmonary disability, reducing mortality and  
426 determining the underlying mechanisms of UC-MSC treatment for COVID-19 disease.

427 **Contributions**

428 FSW ideated and led the study. FSW, WFX, CY and LS designed the study and developed  
429 the protocol. LS, HH, XCL, XY, ZX, LH, JLF and LLS were responsible for study  
430 enrolment. LS, XCL, XY, ZX, LH, JLF were responsible for acquisition, analysis, and  
431 interpretation of data. YZ, WQY, CZ, TYL and JWS were responsible for biorepository  
432 management and biomarker analyses. All authors made substantial contributions to  
433 conduct and coordination of trial and had regular discussions on progress of the study. CY,  
434 YXY and YPY contributed to statistical analysis. LS, RNX and CZ wrote the initial  
435 manuscript draft, and FSW, WFX, MM and AZ critically revised the manuscript. All  
436 authors edited, read and approved the final version before submission.

437 **Funding**

438 This trial was supported by The National Key R&D Program of China (2020YFC0841900,  
439 2020YFC0844000, 2020YFC08860900); The Innovation Groups of the National Natural  
440 Science Foundation of China (81721002); The National Science and Technology Major  
441 Project (2017YFA0105703). The funder of the study had no role in the study design, data  
442 collection, data analysis, data interpretation, or writing of this report. The corresponding  
443 author had full access to all the data in the study and had final responsibility for the  
444 decision to submit for publication.

445

446 **Competing interests**

447 All authors declare no competing interests.

448 **Ethical approval**

449 This study was approved by the Clinical Trial Ethics Committee of Fifth Medical Cente,  
450 Chinese PLA General Hospital (2020-013-D), the Medical Ethics Committee of Wuhan  
451 Huoshenshan Hospital(HSSL004), the Medical Ethics Committee of Maternal and Child  
452 Hospital of Hubei Province(2020IEC001).Written informed consent was obtained from all  
453 the enrolled patients or their legal representatives if they were unable to provide consent.

454 **Data sharing**

455 After approval from the Human Genetic Resources Administration of China, this trial data  
456 can be shared with qualifying researchers who submit a proposal with a valuable research  
457 question. A contract should be signed. See Supplement 12.

458 **Transparency declaration**

459 The lead author\* affirms that this manuscript is an honest, accurate, and transparent  
460 account of the study being reported; that no important aspects of the study have been  
461 omitted; and that any discrepancies from the study as planned (and, if relevant, registered)  
462 have been explained.

463 **Dissemination to participants and related patient and public communities**

464 Participants will be informed of the results of the study by telephone or mail.  
465 Dissemination to the public will be achieved through media outreach.

466 **Acknowledgements**

467 F-S.W, C.Z, M.M., and A.Z. are founder members of the Global Cancer and Infectious  
468 Diseases consortium for Host-Directed therapies (<https://www.fchampalimaud.org/covid19/aci/>)

469 **Additional Contributions**

470 We thank Drs. Sibing Zhang, Dixiong Xu, Fangguo Dai and Bin Liu for logistic support

471 and valuable suggestions to the clinical study. We also thank Fang Lian, Baoqiang Fu,  
472 Yingying Gao and Yan Zhang for their excellent work in follow-up of all enrolled patients.  
473 We thank randomization system provider (Chengdu Cims-medtech), PIATS provider  
474 (Alibaba Health Technology) and academic secretaries (Yufeng Guo, Hairui Si, Lvshuai  
475 Huang, Junqing Luan) for their services. We also thank the People's Government of  
476 Wuhan Municipality for the help in organizing the follow-up work.

477

478 **References**

- 479 1. WHO. Coronavirus disease (COVID-2019) situation reports 2020 [Available from:  
480 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- 481 2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute  
482 respiratory distress syndrome. Lancet Respir Med 2020;8(4):420-22. doi:  
483 [10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X) [published Online First: 2020/02/23]
- 484 3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel  
485 coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. doi:  
486 [10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) [published Online First: 2020/01/28]
- 487 4. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor  
488 prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost  
489 2020;18(4):844-47. doi: [10.1111/jth.14768](https://doi.org/10.1111/jth.14768) [published Online First: 2020/02/20]
- 490 5. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients  
491 reveals distinct immunotypes with therapeutic implications. Science 2020 doi:  
492 [10.1126/science.abc8511](https://doi.org/10.1126/science.abc8511) [published Online First: 2020/07/17]
- 493 6. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune  
494 perturbations associated with severe COVID-19. Sci Immunol 2020;5(49) doi:  
495 [10.1126/sciimmunol.abd7114](https://doi.org/10.1126/sciimmunol.abd7114) [published Online First: 2020/07/17]
- 496 7. Song JW, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and  
497 severe cases of COVID-19. Nat Commun 2020;11(1):3410. doi:  
498 [10.1038/s41467-020-17240-2](https://doi.org/10.1038/s41467-020-17240-2) [published Online First: 2020/07/10]
- 499 8. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the  
500 Science. Immunity 2020;52(6):910-41. doi: [10.1016/j.jimmuni.2020.05.002](https://doi.org/10.1016/j.jimmuni.2020.05.002) [published  
501 Online First: 2020/06/09]
- 502 9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,  
503 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York  
504 City Area. JAMA 2020 doi: [10.1001/jama.2020.6775](https://doi.org/10.1001/jama.2020.6775) [published Online First:  
505 2020/04/23]
- 506 10. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with

- 507 Covid-19 - Preliminary Report. N Engl J Med 2020 doi: 10.1056/NEJMoa2021436  
508 [published Online First: 2020/07/18]
- 509 11. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical  
510 Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized  
511 Clinical Trial. JAMA 2020 doi: 10.1001/jama.2020.10044 [published Online First:  
512 2020/06/04]
- 513 12. Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center  
514 experience. J Med Virol 2020;92(7):814-18. doi: 10.1002/jmv.25801 [published  
515 Online First: 2020/04/08]
- 516 13. Galipeau J, Sensebe L. Mesenchymal Stromal Cells: Clinical Challenges and  
517 Therapeutic Opportunities. Cell Stem Cell 2018;22(6):824-33. doi:  
518 10.1016/j.stem.2018.05.004 [published Online First: 2018/06/03]
- 519 14. Chan MC, Kuok DI, Leung CY, et al. Human mesenchymal stromal cells reduce  
520 influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci  
521 U S A 2016;113(13):3621-6. doi: 10.1073/pnas.1601911113 [published Online First:  
522 2016/03/16]
- 523 15. Chen J, Hu C, Chen L, et al. Clinical study of mesenchymal stem cell treating acute  
524 respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a  
525 hint for COVID-19 treatment. Engineering (Beijing) 2020 doi:  
526 10.1016/j.eng.2020.02.006 [published Online First: 2020/04/16]
- 527 16. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal  
528 stromal cells for moderate to severe acute respiratory distress syndrome (START  
529 study): a randomised phase 2a safety trial. Lancet Respir Med 2019;7(2):154-62. doi:  
530 10.1016/S2213-2600(18)30418-1 [published Online First: 2018/11/21]
- 531 17. Simonson OE, Mougiakakos D, Heldring N, et al. In Vivo Effects of Mesenchymal  
532 Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.  
533 Stem Cells Transl Med 2015;4(10):1199-213. doi: 10.5966/sctm.2015-0021 [published  
534 Online First: 2015/08/20]
- 535 18. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of

- 536 ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3(1):24-32. doi:  
537 10.1016/S2213-2600(14)70291-7 [published Online First: 2014/12/23]
- 538 19. Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome  
539 with allogeneic adipose-derived mesenchymal stem cells: a randomised,  
540 placebo-controlled pilot study. Respir Res 2014;15:39. doi: 10.1186/1465-9921-15-39  
541 [published Online First: 2014/04/09]
- 542 20. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell  
543 therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target  
544 Ther 2020;5(1):172. doi: 10.1038/s41392-020-00286-5 [published Online First:  
545 2020/08/29]
- 546 21. China NHCo. New coronavirus pneumonia prevention and control program (7th edn)  
547 [updated March 4, 2020. Available from:  
548 <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml>.  
549
- 550 22. Zumla A, Wang FS, Ippolito G, et al. Reducing mortality and morbidity in patients with  
551 severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem)  
552 Cell (MSC) therapy - Achieving global consensus and visibility for cellular  
553 host-directed therapies. Int J Infect Dis 2020;96:431-39. doi:  
554 10.1016/j.ijid.2020.05.040 [published Online First: 2020/05/20]
- 555 23. Yang Q, Liu Q, Xu H, et al. Imaging of coronavirus disease 2019: A Chinese expert  
556 consensus statement. Eur J Radiol 2020;127:109008. doi: 10.1016/j.ejrad.2020.109008  
557 [published Online First: 2020/04/27]
- 558 24. Antoine M, Mlika M. Interstitial Lung Disease. StatPearls. Treasure Island (FL)2020.
- 559 25. Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and  
560 outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an  
561 observational study. Lancet Respir Med 2020;8(9):853-62. doi:  
562 10.1016/S2213-2600(20)30316-7 [published Online First: 2020/08/01]
- 563 26. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in  
564 hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:

- 565       prospective   observational   cohort   study.   BMJ   2020;369:m1985.   doi:  
566       10.1136/bmj.m1985 [published Online First: 2020/05/24]
- 567       27. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test.  
568       Am J Respir Crit Care Med 2002;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102  
569       [published Online First: 2002/07/02]
- 570       28. Chen B, Tian EK, He B, et al. Overview of lethal human coronaviruses. Signal  
571       Transduct Target Ther 2020;5(1):89. doi: 10.1038/s41392-020-0190-2 [published  
572       Online First: 2020/06/14]
- 573       29. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. Immunity  
574       2020 doi: 10.1016/j.jimmuni.2020.06.017 [published Online First: 2020/07/02]
- 575       30. Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological responses  
576       in patients with COVID-19. Nat Immunol 2020 doi: 10.1038/s41590-020-0762-x  
577       [published Online First: 2020/08/14]
- 578       31. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells  
579       Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis  
580       2020;11(2):216-28. doi: 10.14336/AD.2020.0228 [published Online First: 2020/04/08]
- 581       32. Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the  
582       treatment of patients with severe COVID-19. Front Med 2020 doi:  
583       10.1007/s11684-020-0810-9 [published Online First: 2020/08/08]
- 584

585 **Figure 1: Trial profile**

586 ITT = intention-to treat population. mITT = modified intention-to treat population

587

588 **Figure 2. Decline in total and consolidation lesion proportion (%) between the**  
589 **umbilical cord-mesenchymal stem cell (UC-MSC) group and placebo group at 28**  
590 **days.**


591 A. Panel A shows the between-group median difference in the change in total lesion  
592 proportion (%) and consolidation lesion proportion (%) of the whole lung volume from  
593 baseline to day 28. I bars indicate the 95%CI described by Hahn and Meeker (1991).

594 B. Panel B shows box plots of the change in the total lesion proportion (%) and  
595 consolidation lesion proportion (%) of the whole lung volume from baseline to day 28.

596 Q1 denotes the first quartile, and Q3 the third quartile. I bars indicate the minimum and  
597 maximum.

598 C. Panel C shows the mean absolute change from baseline in the total lesion proportion (%)  
599 and consolidation lesion proportion (%) of the whole lung volume. I bars indicate the  
600 standard error.


## Figure 1



**Figure 1: Trial profile**

ITT= intention-to treat population. mITT= modified intention-to treat population

## Figure 2



**Figure 2. Decline in total and consolidation lesion proportion (%) between the MSC group and placebo group at 28 day.**

- Panel A shows the between-group median difference in the change in total lesion proportion (%) and consolidation lesion proportion (%) of the whole lung volume from baseline to day 28. I bars indicate the 95%CI described by Hahn and Meeker (1991).
- Panel B shows box plots of the change in the total lesion proportion (%) and consolidation lesion proportion (%) of the whole lung volume from baseline to day 28. Q1 denotes the first quartile, and Q3 the third quartile. I bars indicate the minimum and maximum.
- Panel C shows the mean absolute change from baseline in the total lesion proportion (%) and consolidation lesion proportion (%) of the whole lung volume. I bars indicate the standard error.

**Table 1: Baseline patient characteristics.**

	<b>UC-MSC group (n = 65)</b>	<b>Placebo group (n = 35)</b>
Age, years	60.72(9.14)	59.94(7.79)
Sex – no. (%)		
Men	37 (56.92%)	19 (54.29%)
Women	28 (43.08%)	16 (45.71%)
BMI (Body Mass Index), Kg/m <sup>2</sup> *	24.71(3.19)	25.01(3.12)
Time from symptom onset to baseline, days	45.00(39.00,51.00)	47.00(41.00,53.00)
Any comorbidities	34 (52.31%)	18 (51.43%)
Hypertension	17 (26.15%)	10 (28.57%)
Diabetes	12 (18.46%)	5 (14.29%)
Chronic bronchitis	2(3.08%)	3(8.57%)
Chronic obstructive pulmonary disease	2(3.08%)	0(0.00%)
Concomitant medication		
Antiviral drugs	32 (49.23%)	20 (57.14%)
Antibiotics	27 (41.54%)	12 (34.29%)
Corticosteroids	13 (20.00%)	9 (25.71%)
Lesion proportion (%): total lesion volume (in cm <sup>3</sup> ) / whole lung volume (in cm <sup>3</sup> )	26.31(11.62,38.42)	27.98(11.57,44.14)
Consolidation lesion proportion (%): Consolidation lesion volume (in cm <sup>3</sup> ) / whole lung volume (in cm <sup>3</sup> )	2.59(0.69,5.20)	2.52(0.77,4.91)
Six-category scale		
2-Hospitalized, not requiring supplemental oxygen	14 (21.54%)	10 (28.57%)
3-Hospitalized, requiring supplemental oxygen	50 (76.92%)	25 (71.43%)
4-Hospitalized, on noninvasive ventilation or high flow oxygen devices	1 (1.54%)	0 (0.00%)
White blood cell count* (10 <sup>9</sup> /L)	5.70(5.00,6.60)	5.80(5.00,6.80)
Lymphocyte count (10 <sup>9</sup> /L)	1.39(1.19,1.80)	1.47(1.24,1.84)
CD4 T cells (/μl) †	641.00(482.00,760.00)	734.00(502.00,1031.00)
CD8 T cells (/μl) †	371.00(275.00,520.00)	401.00(307.00,593.00)
B cells (/μl) †	148.50(99.60,251.00)	148.50(94.70,248.00)

NK cells (/μl) †	233.50(151.00,393.00)	197.50(136.00,309.00)
Neutrophil count (10 <sup>9</sup> /L)	3.48(2.91,4.32)	3.83(2.85,4.48)
Platelet count (10 <sup>9</sup> /L)	214.00(174.00,255.00)	210.00(176.00,247.00)
Hemoglobin ( g/L )	122.68 (14.44)	124.26 (11.83)
D-dimer (mg/L) ‡	0.58 (0.36,1.11)	0.56 (0.31,1.12)
IL-6 (pg/ml) §	7.86(5.63,9.84)	8.76(6.54,11.77)
CRP(mg/L) ¶	1.95(0.84,3.53)	1.38(0.68,2.26)
SARS-CoV-2 test result		
SARS-Cov-2 IgG positive	63 (100.00%)	34 (100.00%)
SARS-Cov-2 IgM positive	58 (92.06%)	32 (94.12%)
SARS-Cov-2 nucleic acid detection positive	47(72.31%)	20(57.14%)

Data are median (interquartile range (IQR)), n (%),or mean (SD)

\* BMI values were available for 59 patients in the UC-MSC group and 33 patients in the placebo group.

† CD4, CD8, CD19, and CD56 values were available for 62 patients in the UC-MSC group and 34 patients in the placebo group.

‡ D-dimer values were available for 55 patients in the UC-MSC group and 29 patients in the placebo group.

§ IL-6 values were available for 64 patients in the UC-MSC group and 35 patients in the placebo group.

¶ CRP values were available for 27 patients in the UC-MSC group and 14 patients in the placebo group.

|| The test results are summarized from hospitalization to the pre-random test. If there is any positive, it is defined as positive. The

IgG and IgM values were available for 63 patients in the UC-MSCs group and 34 patients in the placebo group.

**Table 2: Primary and secondary outcomes in the mITT population.**

	UC-MSC group (n = 65)	Placebo group (n = 35)	Difference
Change in the total lesion proportion (%) of the whole lung volume from baseline to day 28	-19.40(-53.40, -2.62)	-7.30(-46.59,19.12)	-13.31(-29.14,2.13) †
Change in consolidation lesion proportion (%) of whole lung volume from baseline to day 28	-57.70(-74.95, -36.56)	-44.45(-62.24, -8.82)	-15.45(-30.82, -0.39) †
Change in ground-glass lesion proportion (%) of whole lung volume from baseline to day 28	-14.95(-51.55,7.29)	-3.94(-43.99,32.55)	-9.84(-30.51,6.86) †
6-minute walking distance at day 28 (meters) *	420.00 (392.00, 465.00)	403.00 (352.00, 447.00)	27.00 (0.00, 57.00) †
VCmax(L) at day 28 ¶	2.57 (2.13, 3.04)	2.49 (2.05, 2.76)	0.16 (-0.10, 0.43) †
DLco (L) at day 28	5.12 (1.62)	5.06 (1.57)	0.07 (-0.69, 0.82)
Six-category scale at day 10			0.77(0.33,1.79) &
1-Not hospitalised;	11(16.92%)	6(17.14%)	
2-Hospitalized, not requiring supplemental oxygen	8(12.31%)	6(17.14%)	
3-Hospitalized, requiring supplemental oxygen	44(67.69%)	23(65.71%)	
4-Hospitalized, on noninvasive ventilation or high flow oxygen devices	2(3.08%)	0(0.00%)	
Duration of oxygen therapy (days) ‡	22.00(13.00,32.00)	31.00(16.00,36.00)	-7.00(-17.00,3.00) †
Finger pulse oxygen in resting state (%) at day 28 §	97.10(1.31)	96.97(1.29)	0.13(-0.42,0.68)
mMRC dyspnea score at day 28 **			1.49(0.68,3.26) &
Grade 0 n(%)	29(47.54%)	13(37.14%)	
Grade 1 n(%)	24(39.34%)	16(45.71%)	
Grade 2 n(%)	5(8.20%)	4(11.43%)	
Grade 3 n(%)	3(4.92%)	1(2.86%)	
Grade 4 n(%)	0(0.00%)	1(2.86%)	

Data are median (interquartile range, IQR), mean (SD) or n (%).

\* In the 6-minute walk test, there were three cases who could not complete the test because of cardiopulmonary function problems. The data were calculated as 0 meters.

† Differences are expressed as Hodges-Lehmann estimator and 95% confidence interval (CI).

¶ VCmax (L) at day 28 were available for 53 patients in the UC-MSC group and 31 patients in the placebo group.

|| DLco (L) at day 28 were available for 53 patients in the UC-MSC group and 27 patients in the placebo group.

&Calculated by ordinal logistic regression model. OR=odds ratio.

‡ Duration of oxygen therapy (days) were available for 29 patients in the UC-MSCs group and 11 patients in the placebo group.

§ Finger pulse oxygen in resting state (%) at day 28 were available for 61 patients in the UC-MSCs group and 35 patients in the placebo group.

\*\* mMRC dyspnea scores were available for 61 patients in the UC-MSCs group and 35 patients in the placebo group.

**Table 3. Summary of adverse events that occurred in the enrolled population of the trial.**

	UC-MSC group (n = 65)		Placebo group (n = 35)	
	Grade 1 or 2	Grade 3 or 4	Grade 1 or 2	Grade 3 or 4
<b>Any adverse event</b>	36 (55.38%)	1 (1.54%)	21 (60.00%)	0 (0.00%)
Increased lactic acid dehydrogenase	9(13.85%)	0(0.00%)	7(20.00%)	0(0.00%)
Increased alanine aminotransferase	7(10.77%)	0(0.00%)	4(11.43%)	0(0.00%)
Hypokalaemia	6(9.23%)	0(0.00%)	1(2.86%)	0(0.00%)
Increased aspartate aminotransferase	5(7.69%)	0(0.00%)	4(11.43%)	0(0.00%)
Increased serum uric acid	5(7.69%)	0(0.00%)	3(8.57%)	0(0.00%)
Diarrhoea	4(6.15%)	0(0.00%)	0(0.00%)	0(0.00%)
Palpitations	3(4.62%)	0(0.00%)	0(0.00%)	0(0.00%)
Increased $\gamma$ -glutamyl transferase	2(3.08%)	0(0.00%)	1(2.86%)	0(0.00%)
Dizziness	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Cough	2(3.08%)	0(0.00%)	1(2.86%)	0(0.00%)
abdominal distention	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Anemia	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Pneumothorax	0(0.00%)	1(1.54%)	0(0.00%)	0(0.00%)
Metabolic alkalosis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Urinary tract infection	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Bacterial infection	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pharyngitis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Increased heart rate	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Creatine phosphate stimulation	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Elevated blood urea	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Poor sleep quality	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Taste reversal	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Chest musculoskeletal	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pulmonary edema	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pharyngeal diseases	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)

Anxious	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Nervous	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Rash	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Thirsty	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Nausea	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Countercurrent	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Non infectious gingivitis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Abdominal pain	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Functional gastrointestinal turbulence	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Vomit	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Gastroesophageal reflux disease	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Toothache	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
heart failure	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Hypocalcemia	0(0.00%)	0(0.00%)	2(5.71%)	0(0.00%)
Hepatic cyst	0(0.00%)	0(0.00%)	2(5.71%)	0(0.00%)
Creatine phosphate stimulation	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Elevated serum creatinine	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Respiratory alkalosis	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Pleural effusion	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Difficulty in falling asleep	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Pruritus	0(0.00%)	0(0.00%)	3(8.57%)	0(0.00%)